Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Income Statement [Abstract]
Grant Revenue	$ 57,480	$ 254,991	$ 336,108	$ 493,063
Operating Expenses:
Research and development	867,345	472,927	1,256,155	1,028,462
General and administrative	990,863	576,918	1,978,622	706,720
Total Operating Expenses	1,858,208	1,049,845	3,234,777	1,735,182
Total Operating Loss	(1,800,728)	(794,854)	(2,898,669)	(1,242,119)
Other Income (Expense):
Research and development credit		9,301		9,301
Interest expense	(51,353)	(61,295)	(115,014)	(118,072)
Net Loss	(1,852,081)	(846,848)	(3,013,683)	(1,350,890)
Net Loss attributable to noncontrolling interest	(37,661)		(59,155)
Net Loss attributable to common stockholders	$ (1,814,420)	$ (846,848)	$ (2,954,528)	$ (1,350,890)
Basic Loss Per Common Share	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.00)
Diluted Loss Per Common Share	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.00)
Weighted Average Number of Common Shares Outstanding - Basic	420,279,879	419,522,119	420,279,879	419,522,119
Weighted Average Number of Common Shares Outstanding - Diluted	420,279,879	419,522,119	420,279,879	419,522,119